Pharsight

Msd Merck Co patents expiration

1. Delstrigo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603282 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(12 years from now)

US10842751 MSD MERCK CO Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Nov, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jan 27, 2025
New Chemical Entity Exclusivity(NCE) Aug 30, 2023
New Indication(I-806) Sep 19, 2022

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: 30 August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: Treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically...

Dosage: TABLET;ORAL

How can I launch a generic of DELSTRIGO before it's drug patent expiration?
More Information on Dosage

DELSTRIGO family patents

Family Patents

2. Emend patents expiration

EMEND's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6096742 MSD MERCK CO Polymorphic form of a tachykinin receptor antagonist
Jul, 2018

(5 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 28, 2018

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage

EMEND family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Pifeltro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8486975 MSD MERCK CO Non-nucleoside reverse transcriptase inhibitors
Oct, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jan 27, 2025
New Indication(I-827) Sep 19, 2022
New Chemical Entity Exclusivity(NCE) Aug 30, 2023

Drugs and Companies using DORAVIRINE ingredient

NCE-1 date: 30 August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current a...

Dosage: TABLET;ORAL

More Information on Dosage

PIFELTRO family patents

Family Patents

4. Recarbrio patents expiration

Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 16, 2024
Generating Antibiotic Incentives Now(GAIN) Jul 16, 2029

Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient

NCE-1 date: 16 July, 2028

Market Authorisation Date: 16 July, 2019

Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

RECARBRIO family patents

Family Patents